Background
==========

Worldwide, prostate cancer is one of the most common causes of cancer death in the male population \[[@b1-medscimonit-24-4807],[@b2-medscimonit-24-4807]\]. In recent years, surgical prostatectomy, radiotherapy, hormone therapy, and immunotherapy have been the major methods used to treat prostate cancer, but treatment options remain limited in advanced-stage disease \[[@b3-medscimonit-24-4807]--[@b7-medscimonit-24-4807]\]. High rates of metastasis and cancer-associated mortality worsen the prognoses of prostate cancer patients, especially for patients with advanced-stage prostate cancer \[[@b8-medscimonit-24-4807]--[@b10-medscimonit-24-4807]\]. It is important to continue to study the molecular mechanisms involved in prostate cancer, which may provide novel perspectives on the diagnosis and treatment of prostate cancer patients in the future.

There is increasing published evidence that has shown that small regulatory noncoding RNAs, such as microRNAs (miRNAs) have a role as biomarkers in human cancer, and are involved in RNA silencing and the down-regulation of gene expression \[[@b11-medscimonit-24-4807]--[@b14-medscimonit-24-4807]\]. Several studies have confirmed that miRNAs play important roles in the development and progression of many types of human cancers \[[@b1-medscimonit-24-4807],[@b15-medscimonit-24-4807]--[@b18-medscimonit-24-4807]\]. The miRNAs may promote tumor development and progression by combining with the 3′-untranslated region (3′-UTR) of target mRNAs \[[@b19-medscimonit-24-4807],[@b20-medscimonit-24-4807]\]. Currently, several studies have shown the expression and potential role of microRNA-99a-3p (miR-99a-3p) in cancer \[[@b21-medscimonit-24-4807]--[@b23-medscimonit-24-4807]\]. For example, miR-99a-3p has been shown to be overexpressed in colorectal cancer and may predict chemotherapy response in patients with advanced colorectal cancer \[[@b22-medscimonit-24-4807]\]. Also, miR-99a-3p has been shown to be down-regulated in endometrioid endometrial carcinoma \[[@b23-medscimonit-24-4807]\]. Although investigators have described the involvement of miRNAs in the biological processes of cancers, including that of miR-99a-3p, little is known about the specific mechanisms involved in the interaction between miR-99a-3p and prostate cancer \[[@b24-medscimonit-24-4807]\].

The aim of this study was to explore the role and mechanism of miR-99a-3p in prostate cancer based on bioinformatics analysis and using a meta-analysis of patient data from a literature review. This study extracted original data provided by The Cancer Genome Atlas (TCGA) database, and twelve miRNA prediction algorithms were utilized to predict the target genes of miR-99a-3p. Gene expression microarrays for prostate cancer were downloaded from the Gene Expression Omnibus (GEO) to select the genes that were differentially expressed in prostate cancer. Further supporting bioinformatics analysis was included from Gene Ontology (GO), the Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) network analysis was applied to investigate the possible mechanism of miR-99a-3p in prostate cancer.

Material and Methods
====================

Validation the expression of microRNA-99a-3p (miR-99a-3p) based on The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and ArrayExpress
--------------------------------------------------------------------------------------------------------------------------------------------------

The Cancer Genome Atlas (TCGA) (*<http://cancergenome.nih.gov/>*) is a database of expression profiles for at least 30 kinds of cancers, including prostate cancer \[[@b25-medscimonit-24-4807]--[@b27-medscimonit-24-4807]\]. TCGA can be used to explore clinicopathological parameters associated with patients with cancer, which were used in this study \[[@b28-medscimonit-24-4807],[@b29-medscimonit-24-4807]\]. In the current study, the RNA sequencing (RNA-Seq) data for prostate cancer patients, which were taken from the Illumina MiSeq RNA-Seq platform, contained 498 prostate cancer cases and 52 normal prostate cases, up to 1st November 2017. The expression data for microRNA-99a-3p (miR-99a-3p) were shown in reads per million (RPM), and miR-99a-3p expression levels were normalized via the 'R' language package DESeq.

The relationship between miR-99a-3p and clinicopathological parameters in prostate cancer cases was further analyzed based on the expression data in TCGA database using a Student's t-test. The receiver-operating characteristic (ROC) curve was utilized to assess the value of miR-99a-3p levels in discriminating between prostate cancer patients and normal controls. The chip datasets from the Gene Expression Omnibus (GEO) were also searched *<http://www.ncbi.nlm.nih.gov/geo/>*), and the public database of microarray gene expression, ArrayExpress was used (*<http://www.ebi.ac.uk/arrayexpress/>*).

For database searches, the following keywords were used: prostate OR prostatic gland OR prostat\* AND cancer OR carcinoma OR tumor OR neoplas\* OR malignan OR adenocarcinoma AND miR OR miRNA OR microRNA OR miR OR miRNA OR microRNA. The expression data for miR-99a-3p were extracted from GEO and ArrayExpress databases.

A literature review of miR-99a-3p and prostate cancer
-----------------------------------------------------

The prostate cancer-related miR-99a-3p microarray data in GEO and ArrayExpress and the RNA-seq data in TCGA were all downloaded. Also, this study included a literature search for for publications related to miR-99a-3p in prostate cancer in twelve online databases: PubMed, Google Scholar, Web of Science, EMBASE, Ovid, Wiley Online Library, LILACS, Science Direct, Cochrane Central Register of Controlled Trials, Chinese CNKI, Wan Fang, Chong Qing VIP, and on the China Biology Medicine disc. The retrieval date was October 30, 2017. The retrieval was performed and checked by two people (Bin-liang Gan and Jie-mei Cen). A group discussion was organized if there were any disagreements. The number of false positives (FP), true positives (TP), true negatives (TN) and false negatives (FN) were extracted.

The potential target genes of miR-99a-3p
----------------------------------------

In the present study, twelve online target prediction algorithms were selected to predict the target genes of miR-99a-3p. These twelve algorithms were used were miRWalk (*<http://zmf.umm.uni-heidelberg.de/>*), miRmap (*<http://mirmap.ezlab.org/>*), miRecords (*<http://c1.accurascience.com/miRecords/>*), DIANA-mT (*<http://diana.imis.athena-innovation.gr/>*), miRanda (*<http://www.microrna.org>*), miRDB (*<http://www.mirdb.org/>*), RNAhybrid (<http://bibiserv2.cebitec.uni-bielefeld.de/>), PICTAR4 (*<http://pictar.mdc-berlin.de/cgi-bin/PicTar_vertebrate.cgi>*), PICTAR5 (*<http://pictar.mdc-berlin.de/cgi-bin/new_PicTar_vertebrate.cgi>*), PITA (*<http://genie.weizmann.ac.il/>*), RNA22 (*<http://cbcsrv.watson.ibm.com/rna22.html>*), and TargetScan (*<http://www.targetscan.org/>*). A Venn diagram tool (*<http://bioinformatics.psb.ugent.be/webtools/Venn/>*) was chosen for the identification of candidate genes. Genes that were concurrently predicted by more than two target prediction algorithms were selected for further analysis.

Also, the gene expression microarrays for prostate cancer were downloaded from GEO using the following keywords: miR-99a-3p OR miRNA-99a-3p OR microRNA-99a-3p AND prostate OR prostatic gland OR prostat\* AND cancer OR carcinoma OR tumor OR neoplas\* OR malignan OR adenocarcinoma. Then, the genes that were differentially expressed in prostate cancer were selected.

The potential functions and pathways associated with miR-99a-3p
---------------------------------------------------------------

To further explore the potential functions and pathways associated with miR-99a-3p, bioinformatics analysis, including Gene Ontology (GO), the Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) network analysis, were applied to study the underlying functions, networks, and pathways of the genes \[[@b30-medscimonit-24-4807]--[@b32-medscimonit-24-4807]\]. The DAVID Bioinformatics Tool (*<https://david.ncifcrf.gov/>*, Version 6.7) was utilized to perform the GO and KEGG analysis \[[@b33-medscimonit-24-4807]--[@b35-medscimonit-24-4807]\]. Biological process (BP), cellular component (CC) and molecular function (MF) data were exported from GO. Cytoscape (Version 3.0) (*<http://cytoscape.org>*) was used to create the functional network between miR-99a-3p and the potential genes.

Construction of the protein-protein interaction (PPI) network
-------------------------------------------------------------

The interaction pairs of the potential genes were surveyed by using the Search Tool for the Retrieval of Interacting Genes (STRING) Version 9.0 (*<http://string-db.org>*) \[[@b34-medscimonit-24-4807],[@b36-medscimonit-24-4807],[@b37-medscimonit-24-4807]\]. A STRING database has been constructed to provide a global perspective for as many species as possible, including humans. The known and predicted relationships were integrated and scored, and a combined score of \>0.4 was recognized in the construction of the PPI network.

Identification of miR-99a-transcription factors (TFs)
-----------------------------------------------------

The CircuitsDB (*<http://biocluster.di.unito.it/circuits>*) database is a web-server used to research miRNA transcription factor (TF) regulatory circuits in humans and mice \[[@b38-medscimonit-24-4807]\]. The TFs were extracted from the CircuitsDB database, and a regulatory network was constructed between miR-99a-3p and these TFs using Cytoscape software (Version 3.0).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS version 22.0 (SPSS, IBM, Chicago, IL, USA). A student's t-test was carried to compare the expression of miR-99a-3p in prostate cancer and normal prostate tissue. A receiver-operating characteristic (ROC) curve was created to differentiate prostate cancer from normal prostate tissues via miR-99a-3p expression. Spearman's rank correlation coefficient was used to determine the relationship between miR-99a-3p and potentially associated genes. P\<0.05 (two-sided) was considered to indicate statistical significance.

Results
=======

The expression of microRNA-99a-3p (miR-99a-3p) based on The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and ArrayExpress
---------------------------------------------------------------------------------------------------------------------------------------

The original data from The Cancer Genome Atlas (TCGA) was further investigated and showed that miR-99a-3p was significantly down-regulated in prostate cancer when compared with non-cancerous prostate tissues (P\<0.001) ([Figure 1A](#f1-medscimonit-24-4807){ref-type="fig"}). The relationship between miR-99a-3p and the clinicopathological parameters of prostate cancer showed that high expression levels of miR-99a-3p were positively related to lymph node metastasis (P=0.023) ([Figure 1B](#f1-medscimonit-24-4807){ref-type="fig"}; [Table 1](#t1-medscimonit-24-4807){ref-type="table"}). Also, the receiver-operating characteristic (ROC) curve showed that the area under the curve (AUC) for miR-99a was 0.660 (95% CI 0.587--0.732) (P\<0.001) for prostate cancer patients, which reflected the moderate level of the ability of miR-99a-3p to discriminate between prostate cancer patients and normal controls ([Figure 1C](#f1-medscimonit-24-4807){ref-type="fig"}). The correlations between the expression of miR-99a-3p and other clinical parameters in prostate cancer were explored, but no positive associations were identified from the TCGA data.

Also, seven clip datasets (GSE21036, GSE23022, GSE24201, GSE31568, GSE34932, GSE36802, and E-MTAB-408) were chosen based on GEO and ArrayExpress. The detailed characteristics of the microarray datasets included in the study are shown in [Table 2](#t2-medscimonit-24-4807){ref-type="table"}. A Student's t-test was applied to compare miR-99a-3p expression in prostate cancer with normal prostate tissues. The down-regulated expression of miR-99a-3p in prostate cancer was found in GSE21036, GSE24201, and GSE36802, whereas GSE23022, GSE31568, GSE34932, and E-MTAB-408 showed upregulation of expression of miR-99a-3p in prostate cancer ([Figure 2A--2G](#f2-medscimonit-24-4807){ref-type="fig"}).

Analysis from the literature review of the association between miR-99a-3p and prostate cancer: The identification of 965 cases
------------------------------------------------------------------------------------------------------------------------------

The literature review identified 965 cases from three centers (six datasets from GEO, one dataset from ArrayExpress, and the original data from TCGA). The procedure involved in the analysis is shown in [Figure 3](#f3-medscimonit-24-4807){ref-type="fig"}. For miR-99a-3p expression in the prostate cancer group, compared with the normal group, a fixed-effect model was first used to calculate the standard mean deviation (SMD). The combined SMD reached −0.26 (−0.44, −0.09), with high heterogeneity (I^2^=86.8%) (P\<0.05), indicating the down-regulation of expression of miR-99a-3p in prostate cancer cases ([Figure 4A](#f4-medscimonit-24-4807){ref-type="fig"}).

A random-effect model was used, and the combined SMD reached −0.06 (−0.58, 0.45), with heterogeneity of \>50% ([Figure 4B](#f4-medscimonit-24-4807){ref-type="fig"}). To investigate whether a certain study had contributed to this heterogeneity, a sensitivity analysis was applied, and this sensitivity analysis showed that the pooled SMD was stable ([Figure 4C](#f4-medscimonit-24-4807){ref-type="fig"}). Also, no significant publication bias was found ([Figure 4D](#f4-medscimonit-24-4807){ref-type="fig"}).

The diagnostic analysis demonstrated that the area under the curve (AUC) of the summary receiver-operating characteristic (SROC) curve was 0.62 (0.57--0.66) ([Figure 5A](#f5-medscimonit-24-4807){ref-type="fig"}), with a sensitivity and specificity of 0.38 (95% CI, 0.12--0.73) and 0.80 (95% CI, 0.38--0.96), respectively ([Figure 5B](#f5-medscimonit-24-4807){ref-type="fig"}). Also, the results confirmed the AUC (0.660) of the original data from TCGA, which indicated the moderate value of miR-99a-3p in predicting prostate cancer. The negative and positive diagnostic likelihood ratio (DLR) values were 0.77 (0.49--1.22) and 1.89 (0.57--6.27), respectively ([Figure 5C](#f5-medscimonit-24-4807){ref-type="fig"}). A DLR value of 1.89 suggested that patients with prostate cancer had an approximately 1.89-fold greater chance of being miR-99a-3p assay-positive. The diagnostic score and odds ratio (OR) were 0.89 (−0.65--2.43) and 2.44 (0.52--11.39), respectively ([Figure 5D](#f5-medscimonit-24-4807){ref-type="fig"}). No significant publication bias was found (P=0.44) ([Figure 5E](#f5-medscimonit-24-4807){ref-type="fig"}).

Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis
------------------------------------------------------------------------------------------

Based on the twelve target prediction algorithms, 1,062 genes were predicted by more than two prediction algorithms. Furthermore, only one gene dataset (GSE85614) was found to relate to miR-99a-3p in prostate cancer. Genes found to be upregulated (≥2 fold change) in GSE85614 were selected. A total of 5,270 differentially expressed genes were selected. Also, 156 genes were found to overlap in both prediction algorithms (1,062) and the GEO database (5,270). These 156 genes were used for the GO and pathway analysis. The GO analysis showed that the strongly enriched terms were protein phosphorylation, translation repressor activity, and protein binding ([Figure 6](#f6-medscimonit-24-4807){ref-type="fig"}; [Table 3](#t3-medscimonit-24-4807){ref-type="table"}). The KEGG pathway analysis showed that miR-99a-3p was associated with different pathways, the Wnt and vascular endothelial growth factor (VEGF) signaling pathways ([Figure 7](#f7-medscimonit-24-4807){ref-type="fig"}; [Table 4](#t4-medscimonit-24-4807){ref-type="table"}). When analyzed together, the GO and KEGG pathway items indicated that miR-99a-3p might be involved in biological mechanisms of prostate cancer.

A network of these 156 genes was constructed ([Figure 8](#f8-medscimonit-24-4807){ref-type="fig"}). The relationships between miR-99a-3p and the differentially expressed genes were observed from this network. A protein-protein interaction (PPI) network was constructed using STRING online, and a total of 72 PPI pairs with combined scores \>0.4 were noted ([Figure 9](#f9-medscimonit-24-4807){ref-type="fig"}). Also, *PPP2CA, LYN*, *TRRAP*, *PPP3CA*, *PIK3CD*, and *HYOU1* were found to have higher degrees of association (\>5) according to the PPI network. Also, investigation of the expression levels of these six genes and their correlations with miR-99a-3p was based on TCGA, which showed that only the protein phosphatase 3 catalytic subunit alpha (*PPP3CA*) gene and the hypoxia upregulated protein 1 (*HYOU1*) gene were more highly expressed in prostate cancer tissue when compared with normal prostate tissue (P\<0.01) ([Figure 10A, 10B](#f10-medscimonit-24-4807){ref-type="fig"}). However, there was a negative correlation between expression of miR-99a-3p and both *PPP3CA* (r=−0.049, P=0.276) ([Figure 10C](#f10-medscimonit-24-4807){ref-type="fig"}) and *HYOU1* (r=−0.058, P=0.195) ([Figure 10D](#f10-medscimonit-24-4807){ref-type="fig"}).

The AUC values of *PPP3CA* and *HYOU1* were 0.776 (95% CI, 0.721--0.832) (P\<0.001) ([Figure 10E](#f10-medscimonit-24-4807){ref-type="fig"}) and 0.668 (95% CI, 0.604 −0.732) (P\<0.001) ([Figure 10F](#f10-medscimonit-24-4807){ref-type="fig"}), respectively. The Human Protein Atlas (HPA) database (*<http://www.proteinatlas.org/>*) was used to clarify the protein levels of PPP3CA and HYOU1. As shown in [Figure 11A--11D](#f11-medscimonit-24-4807){ref-type="fig"}, immunostaining for PPP3CA and HYOU1 protein expression were both positive in prostate cancer tissues.

Based on the results described above, it might be possible to hypothesize that miR-99a-3p may influence the expression of the *PPP3CA* or *HYOU1* genes that encode proteins involved in prostate cancer. [Figure 12](#f12-medscimonit-24-4807){ref-type="fig"} shows the regulatory network of miR-99a-3p and transcription factors, constructed using Cytoscape, an open source bioinformatics software platform to visualize molecular networks and their integrating and interaction with gene expression profiles (*[www.cytoscape.org](www.cytoscape.org)*).

Discussion
==========

The initial aim of this study was to investigate the expression levels of microRNA-99a-3p (miR-99a-3p) in prostate cancer based on The Cancer Genome Atlas (TCGA), and the results showed that miR-99a-3p was down-regulated in prostate cancer compared with normal prostate tissue. The receiver operating characteristic (ROC) curve showed that miR-99a-3p might have a moderate ability to discriminate between prostate cancer patients and normal controls.

The present study was the first include a meta-analysis evaluating the expression and diagnostic value of miR-99a-3p in prostate cancer. As a result, the standard mean deviation (SMD) was −0.26 (−0.44, −0.09) and this meta-analysis verified the down-regulated expression of miR-99a-3p in prostate cancer. In the diagnostic meta-analysis, 965 cases from the Gene Expression Omnibus (GEO), TCGA, and ArrayExpress were included, and the results were utilized to assess the ability of miR-99a-3p to detect prostate cancer. However, this meta-analysis had several limitations. A high level of heterogeneity was unavoidable, partly because blinding was present in only three included databases (GEO, ArrayExpress, and TCGA). Also, the different expression trends for miR-99a-3p in GEO and ArrayExpress may also have contributed to the high heterogeneity.

To further explore the potential functions and pathways associated with miR-99a-3p, bioinformatics analysis was applied to investigate the underlying functions, pathways, and networks of the genes. The Gene Ontology (GO) terms of protein phosphorylation, translation repressor activity, and protein binding were found to be highly enriched. Also, miR-99a-3p might be associated with the Wnt and vascular endothelial growth factor (VEGF) signaling pathways.

Protein-protein interaction (PPI) network analysis was used investigate the most likely target genes for miR-99a-3p in prostate cancer and *PPP2CA*, *LYN*, *TRRAP*, *PPP3CA*, *PIK3CD*, and *HYOU1* were selected. Thee protein phosphatase 3 catalytic subunit alpha (*PPP3CA*) gene and the hypoxia upregulated protein 1 (*HYOU1*) gene were more highly expressed in prostate cancer tissue when compared with normal prostate tissue, and negative correlations were found between miR-99a-3p and both *PPP3CA* and *HYOU1*. Therefore, it might be possible to propose that miR-99a-3p has a role in prostate cancer by influencing *PPP3CA* or *HYOU1* gene expression and by contributing to pathways including the Wnt and VEGF signaling pathways. However, further functional studies are required to verify these preliminary findings.

Several previously published studies have confirmed the significant role of miR-99a in prostate cancer. For example, Sun et al. \[[@b19-medscimonit-24-4807]\] found that miR-99 family members, including miR-99a, -99b, and -100, were all down-regulated in prostate cancer, which was consistent with the results of the present study, and also that miR-99a can suppress prostate cancer cell proliferation and prostate-specific antigen expression. Rane et al. \[[@b39-medscimonit-24-4807]\] clarified that low expression levels of miR-99a are relatively radiation-insensitive and that miR-99a could be a marker of radiation sensitivity and thus a therapeutic target to improve the efficiency of radiotherapy. As previously reported, miR-99a may play important roles in cancers via target genes. For example, miR-99a might inhibit cell proliferation through targeting TNFAIP8 in osteosarcoma cells \[[@b40-medscimonit-24-4807]\]. In breast cancer, miR-99a might inhibit aggressive tumor phenotypes via regulating *HOXA1* \[[@b41-medscimonit-24-4807]\]. However, miR-99a has been shown to promote cell proliferation via targeting *FGFR3* in ovarian cancer cells \[[@b42-medscimonit-24-4807]\].

From the findings of the present study, it might be possible to hypothesize that miR-99a-3p has a role in prostate cancer by targeting the *PPP3CA* or *HYOU1* genes. As previously reported, *PPP3CA* is a target of miR-145 and thus be involved in caspase-dependent and caspase-independent cell death in urothelial cancer cells \[[@b43-medscimonit-24-4807]\]. Also, *PPP3CA* has been shown to have a role in breast cancer, lung cancer, and Wilson's disease \[[@b44-medscimonit-24-4807]--[@b46-medscimonit-24-4807]\]. The *HYOU1* gene has been found to be upregulated in nasopharyngeal carcinoma and may act as a molecular biomarker for the progression and prognosis of this type of cancer \[[@b47-medscimonit-24-4807]\]. Also, the expression of the *HYOU1* gene is associated with lymph node involvement in colorectal cancer \[[@b48-medscimonit-24-4807]\]. However, the findings of the present study are preliminary, and the roles of the *PPP3CA* and *HYOU1* genes in prostate cancer should be confirmed by both further functional and clinical studies.

Conclusions
===========

The findings of this study showed that in patients with prostate cancer, expression of microRNA-99a-3p (miR-99a-3p) was associated with the Wnt and vascular endothelial growth factor (VEGF) signaling pathways and inhibited the expression of the protein phosphatase 3 catalytic subunit alpha (*PPP3CA*) gene and the hypoxia upregulated protein 1 (*HYOU1*) gene. The Wnt signaling pathway has been previously reported to be associated with metastasis, proliferation, apoptosis, and the cell cycle in prostate cancer \[[@b49-medscimonit-24-4807]--[@b51-medscimonit-24-4807]. In previously published studies, the VEGF signaling pathway has been shown to be associated with tumor angiogenesis and tumor progression \[[@b52-medscimonit-24-4807]--[@b55-medscimonit-24-4807]\]. Therefore, from the findings of this study, miR-99a-3p might have a role in prostate cancer by targeting the *PPP3CA* or *HYOU1* and contributing to the Wnt and VEGF signaling pathways. However, these preliminary findings require further molecular and functional studies and large-scale controlled clinical studies to determine the role of microRNAs, including miR-99a-3p, in prostate cancer.
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![Clinical significance of microRNA-99a-3p (miR-99a-3p) in prostate cancer based on The Cancer Genome Atlas (TCGA) database. (**A**) Differential expression of microRNA-99a-3p (miR-99a-3p) between prostate cancer tissue and non-cancerous prostate tissue. (**B**) Differential expression of miR-99a-3p in cases with lymph node metastasis compared with those without lymph node metastasis. (**C**) The receiver-operating characteristic (ROC) curve for miR-99a-3p in prostate cancer.](medscimonit-24-4807-g001){#f1-medscimonit-24-4807}

![Differential expression of microRNA-99a-3p (miR-99a-3p) in prostate cancer based on the Gene Expression Omnibus (GEO) and ArrayExpress datasets. (**A**) GSE21036. (**B**) GSE24201. (**C**) GSE36802. (**D**) GSE23022. (**E**) GSE31568. (**F**) GSE34932. (**G**) E-MTAB-408.](medscimonit-24-4807-g002){#f2-medscimonit-24-4807}

![The procedures involved in the meta-analysis of the literature review.](medscimonit-24-4807-g003){#f3-medscimonit-24-4807}

![The expression conditions of microRNA-99a-3p (miR-99a-3p) in prostate cancer tissue compared with normal prostate tissue. (**A**) Forest plot of the datasets evaluating microRNA-99a-3p (miR-99a-3p) expression in prostate cancer patients compared with normal control groups (fix-effects model). (**B**) Forest plot of datasets evaluating miR-99a-3p expression between prostate cancer and normal control groups (random-effects model). (**C**) Sensitivity analysis to exclude the main studies one at a time. (**D**) Funnel plot of datasets, indicating that no publication bias was found in the analysis.](medscimonit-24-4807-g004){#f4-medscimonit-24-4807}

![The meta-analysis of the literature review of published studies on microRNA-99a-3p (miR-99a-3p) and prostate cancer included 965 cases of prostate cancer. (**A**) The summary receiver-operating characteristic (SROC) curve, which represents the performance of the association of miR-99a-3p with prostate cancer, based on data from a meta-analysis. (**B**) The pooled sensitivity and specificity of the included studies. (**C**) The pooled positive diagnostic likelihood ratio (DLR) and negative DLR values of the included studies. The diagnostic DLR is the ratio of the likelihood of the observed test result in patients with prostate cancer *vs.* a population without prostate cancer. (**D**) The pooled diagnostic score and diagnostic odds ratio (OR) of the included studies. (**E**) The publication bias: 1/root (ESS) refers to the inverse root of the effective sample size. Each circle represents an included study.](medscimonit-24-4807-g005){#f5-medscimonit-24-4807}

![Distribution of Gene Ontology (GO) terms for the target genes of microRNA-99a-3p (miR-99a-3p) in prostate cancer. (**A**) Biological process (BP). (**B**) Cellular component (CC). (**C**) Molecular function (MF).](medscimonit-24-4807-g006){#f6-medscimonit-24-4807}

![Distribution of the Kyoto Encyclopedia of Genes and Genomes (KEGG) terms for the target genes of microRNA-99a-3p (miR-99a-3p) in prostate cancer.](medscimonit-24-4807-g007){#f7-medscimonit-24-4807}

![Network analysis between microRNA-99a-3p (miR-99a-3p) and the target genes.](medscimonit-24-4807-g008){#f8-medscimonit-24-4807}

![The protein-protein interaction (PPI) network of the target genes, created using STRING online.](medscimonit-24-4807-g009){#f9-medscimonit-24-4807}

![Clinical significance of the expression of the *PPP3CA* and *HYOU1* genes in prostate cancer, based on The Cancer Genome Atlas (TCGA) database. (**A**) The differential expression of *PPP3CA* in tissue containing prostate cancer compared with normal, non-cancerous prostate tissue. (**B**) The differential expression of *HYOU1* in tissue containing prostate cancer compared with normal, non-cancerous prostate tissue. (**C**) The negative correlation between *PPP3CA* and miR-99a-3p. (**D**) The negative correlation between *HYOU1* and miR-99a-3p. (**E**) The receiver-operating characteristic (ROC) curve for *PPP3CA* in prostate cancer. (**F**) The ROC curve for *HYOU1* in prostate cancer.](medscimonit-24-4807-g010){#f10-medscimonit-24-4807}

![The immunohistochemical staining for protein phosphatase 3 catalytic subunit alpha (PPP3CA) and the hypoxia upregulated protein 1 (HYOU1) protein in prostate cancer tissues. (**A, B**) Prostate cancer tissues show positive immunostaining of cancer cells with antibody HPA012778 to protein phosphatase 3 catalytic subunit alpha (PPP3CA). (**C, D**) Prostate cancer tissues show positive immunostaining of cancer cells with antibody HPA049296 to the hypoxia upregulated protein 1 (HYOU1) protein.](medscimonit-24-4807-g011){#f11-medscimonit-24-4807}

![The regulatory network of microRNA-99a-3p (miR-99a-3p) and transcription factors, constructed using Cytoscape. Cytoscape is an open source bioinformatics software platform to visualize molecular networks and their integrating and interaction with gene expression profiles (*[www.cytoscape.org](www.cytoscape.org)*).](medscimonit-24-4807-g012){#f12-medscimonit-24-4807}

###### 

Differential expression of miR-99a and clinicopathological parameters in prostate cancer based on TCGA.

  Clinicopathological features   N                 miR-99a expression                            
  ------------------------------ ----------------- -------------------- -------------- --------- ---------
  Tissues                        Normal prostate   52                   13.685±0.722   −4.304    \<0.001
  Prostate cancer                498               13.216±0.955                                  
  Age                            \<60              201                  13.215±0.976   0.103     0.917
  ≥60                            203               13.205±0.938                                  
  Race                           White             146                  13.275±1.003   F=0.276   0.759
  Black                          7                 13.120±0.792                                  
  Asian                          2                 12.826±0.649                                  
  Stage                          I+II              187                  13.265±1.016   0.153     0.347
  III+IV                         300               13.182±0.918                                  
  T (tumor)                      T1+T2             348                  13.219±0.904   0.190     0.349
  T3+T4                          55                13.091±1.183                                  
  N (node)                       Yes               78                   13.415±0.953   −2.277    0.023
  No                             344               13.14±0.965                                   
  M (metastasis)                 Yes               3                    12.936±1.278   0.506     0.613
  No                             454               13.220±0.968                                  

###### 

Characteristics of microarray datasets included in the study.

  First author (publication year)   Country   Data source                Test method/ Platform   Cancer group   Normal controls   Mean1 ±SD1     Mean0 ±SD0
  --------------------------------- --------- -------------------------- ----------------------- -------------- ----------------- -------------- ---------------
  Taylor B. et al. (2010)           USA       GEO: GSE21036              Agilent GPL8227         113            28                3.778±0.648    4.518±0.33
  Wach S. et al. (2010)             Germany   GEO: GSE23022              Affymetrix GPL8786      20             20                0.921±0.177    0.909±0.228
  Mattila H. et al. (2010)          Finland   GEO: GSE24201              Agilent GPL7731         14             15                15.684±5.269   16.757±8.92
  Keller A. et al. (2011)           Germany   GEO: GSE31568              Febit GPL9040           23             70                49.266±49.74   42.421±34.322
  Zhong W. et al. (2012)            China     GEO: GSE34932              Agilent GPL11487        9              7                 1.773±0.766    1.406±0.293
  Lin P.C. et al. (2012)            USA       GEO: GSE36802              Affymetrix GPL8786      21             21                6.197±1.993    6.788±0.952
  Jalava S.E. et al. (2012)         Finland   ArrayExpress: E-MTAB-408   Agilent A-MEXP-1663     28             26                3.138±0.792    1.811±1.371
  TCGA (2017)                       USA       TCGA                       NR                      498            52                13.216±0.955   13.685±0.722

Mean1 ±SD1 -- prostate cancer tissues; Mean0 ±SD0 -- non-tumor tissues.

###### 

Top-six enrichment GO terms (BP, CC, and MF) of the target genes of miR-99a-3p.

  ID            Term                                                                   Ontology   Count   Fold enrichment   P
  ------------- ---------------------------------------------------------------------- ---------- ------- ----------------- ----------
  GO: 0045944   Positive regulation of transcription from RNA polymerase II promoter   BP         15      1.82098163        0.034475
  GO: 0006468   Protein phosphorylation                                                BP         9       2.350503919       0.037316
  GO: 0030335   Positive regulation of cell migration                                  BP         7       4.530681468       0.004461
  GO: 0038095   Fc-epsilon receptor signaling pathway                                  BP         6       4.014343772       0.016754
  GO: 0071300   Cellular response to retinoic acid                                     BP         4       6.80526849        0.020687
  GO: 0034976   Response to endoplasmic reticulum stress                               BP         4       6.351583924       0.024768
  GO: 0005634   Nucleus                                                                CC         63      1.493129414       0.000222
  GO: 0016020   Membrane                                                               CC         29      1.691728553       0.005267
  GO: 0005654   Nucleoplasm                                                            CC         32      1.475149749       0.021198
  GO: 0000932   Cytoplasmic mRNA processing body                                       CC         4       6.581437342       0.022627
  GO: 0042470   Melanosome                                                             CC         4       5.082694185       0.043657
  GO: 0005829   Cytosol                                                                CC         35      1.355001806       0.046229
  GO: 0030371   Translation repressor activity                                         MF         3       31.75109718       0.003779
  GO: 0005524   ATP binding                                                            MF         23      1.791087533       0.008073
  GO: 0005515   Protein binding                                                        MF         88      1.166194728       0.02601
  GO: 0031624   Ubiquitin conjugating enzyme binding                                   MF         3       11.26651835       0.02859
  GO: 0015276   Ligand-gated ion channel activity                                      MF         3       9.701724138       0.037683
  GO: 0008270   Zinc ion binding                                                       MF         17      1.693029704       0.041044

###### 

Top-ten KEGG pathway enrichment analysis of the target genes of miR-99a-3p.

  KEGG ID    KEGG term                                Count   Fold Enrichment   P
  ---------- ---------------------------------------- ------- ----------------- ----------
  hsa05166   HTLV-I infection                         10      4.152644231       0.000528
  hsa04662   B cell receptor signaling pathway        5       7.703455964       0.003688
  hsa04022   cGMP-PKG signaling pathway               7       4.482854495       0.004163
  hsa04310   Wnt signaling pathway                    6       4.622073579       0.00877
  hsa04922   Glucagon signaling pathway               5       5.369075369       0.013068
  hsa04931   Insulin resistance                       5       4.921652422       0.017494
  hsa04370   VEGF signaling pathway                   4       6.970996217       0.018625
  hsa04722   Neurotrophin signaling pathway           5       4.429487179       0.024709
  hsa04360   Axon guidance                            5       4.185342217       0.029641
  hsa04261   Adrenergic signaling in cardiomyocytes   5       3.640674394       0.045801
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